查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1860469

单核细胞活化检测市场按产品类型、应用、技术和最终用户划分 - 全球预测（2025-2032 年）

Monocyte Activation Tests Market by Product Type, Application, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，单核细胞活化测试市场将成长至 10.9,085 亿美元，复合年增长率为 8.09%。

关键市场统计数据
基准年 2024 5.8509亿美元
预计年份：2025年 6.2921亿美元
预测年份 2032 1,090,850,000 美元
复合年增长率 (%) 8.09%

本书深入浅出地介绍了单核细胞活化检测如何在快速发展的生命科学生态系统中将免疫毒理学、生技药品安全性和临床实验室实践联繫起来。

单核细胞活化试验已成为连结免疫毒理学、生技药品安全性和临床诊断的重要检测手段。这些试验透过测量单核细胞在接触药物、候选疫苗或生物污染物后的功能活化来评估先天免疫反应。随着治疗方法日益复杂，生技药品在开发平臺占据主导地位，监管机构和临床检查室需要可靠且可重复的方法来检测免疫刺激性杂质，从而确保从生产到临床应用的安全性。

近期技术进步、监管要求变化以及整合解决方案模式正在从根本上重塑单核细胞活化检测及其应用趋势。

单核细胞活化检测领域正经历变革性的转变，这主要得益于技术创新、不断变化的监管要求以及对转化安全性评估日益增长的重视。高灵敏度的检测平台和混合检测方法正在拓展这些检测的分析窗口，从而能够早期、精准地识别复杂生物基质中的免疫刺激讯号。这种技术的成熟正在重塑工作流程，检查室越来越多地将基于仪器的测量与先进的生物资讯学相结合，以改善讯号解读并减少假阳性结果。

检验到 2025 年，累积关税压力如何重塑单核细胞活化检测相关人员的供应链、筹资策略和营运模式。

美国关税政策的累积影响将持续到2025年，为从事单核细胞活化检测的製造商和实验室带来了新的营运挑战。关税带来的成本压力正在影响专用设备、试剂和耗材的供应链，这些产品通常来自国际合作伙伴。为了应对这项挑战，一些供应商正在拓展供应商网络，并将部分生产过程本地化，以降低进口关税的影响，并提高供应链的韧性。这些策略调整将影响前置作业时间、单价结构和供应商选择标准。

一种精细化的细分观点，将单核细胞活化检测中的产品、应用、技术和最终用户与策略机会和优先事项联繫起来。

了解关键细分市场趋势对于驾驭单核细胞活化检测市场、制定符合终端用户需求的产品和市场推广策略至关重要。按产品类型划分，该市场包括仪器、试剂盒及试剂以及服务。仪器包括酵素连结免疫吸附测定仪 (ELISA)、流式细胞仪和微阵列扫描仪；试剂盒及试剂包括细胞培养基、细胞激素检测试剂和单核细胞活化试剂；服务包括合约检测服务、客製化检测开发和验证服务。这种以产品为中心的观点突显了创新重点领域以及可以透过伙伴关係加速产品上市的途径。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和应用模式将影响单一点激活测试的应用、监管和商业化路径。

区域趋势将显着影响单核细胞活化检测的普及率、监管路径和商业化策略。在美洲，强大的生物製药生态系统和完善的法规结构为先进检测方法的推广应用创造了有利环境，密集的合约实验室网路和临床研究领域的早期采用者推动了市场需求。该地区毗邻大型临床试验中心和主要治疗药物研发公司的总部，有利于进行试验计画和合作检验研究。

单核细胞活化检测生态系中，仪器製造商、试剂专家和服务供应商之间的关键竞争动态和差异化策略

单核细胞活化检测领域的竞争格局呈现出仪器製造商、专业试剂供应商和服务型合约供应商三者并存的局面，各方都在寻求差异化的价值提案。仪器供应商在灵敏度、通量和整合能力方面展开竞争，通常将硬体与专有软体和试剂包结合，以提升客户忠诚度。试剂供应商则强调检测的特异性、稳定性以及符合法规要求的品管，以吸引註重检验的客户。同时，服务供应商凭藉灵活的检测设计、快速的结果交付和深厚的法规专业知识脱颖而出，帮助生物製药客户缩短研发週期并降低申报风险。

为加强产品检验、提供全面服务、提高供应链韧性、建立客户支援系统和提高资料互通性以确立市场领导地位，提出切实可行的策略建议。

产业领导者应立即采取切实可行的措施，以巩固其市场地位并加速单核细胞活化检测的价值创造。首先，应优先投资于检测方法的标准化、性能检验和全面的技术文檔，以促进监管审查和实验室间结果的可重复性。这些措施将减轻顾客负担，并增强顾客对贵公司价值主张的信心。其次，应发展多通路伙伴关係，将仪器销售、试剂供应和服务交付结合，提供满足客户端到端需求的整合解决方案，从而提高收入的可预测性。

本文简要介绍了为得出这些结论而采用的严谨的混合方法研究方法，该方法结合了相关人员访谈、监管审查和技术性能分析。

本执行摘要的研究采用了混合方法，整合了技术、法规和商业性的见解。主要研究包括对检查室主任、验证科学家和采购经理进行结构化访谈，以及咨询法规专家，以了解他们对检测验收标准的细緻看法。次要研究包括查阅同行评审文献、法规指导文件和产品技术规范，检验性能声明并分析技术权衡。

简明扼要的结论综合阐述了单核细胞活化检测的长期优势策略、检验重点以及对营运韧性的影响。

总之，单核细胞活化试验处于科学创新、监管审查和操作复杂性的交汇点。检测技术的成熟以及对可靠免疫毒性评估需求的不断增长，提升了这些试验对生物治疗药物研发者和临床检查室的战略重要性。同时，关税趋势和区域监管差异等外部压力要求企业制定适应性强的商业策略和建立具有韧性的供应链。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 引进自动化微流体平台进行单核细胞即时活化分析在监管检测的应用
  • 将人工智慧演算法整合到个人化医疗流程中，用于预测单核细胞活化谱
  • 开发一种用于同时检测单核细胞活化生物标记的多重流式细胞技术检测方法
  • 推出用于细胞治疗生产中内毒素检测的标准化单核细胞活化测试试剂盒
  • 拓展CRO服务，为疫苗研发提供客製化的单核细胞活化检测。
  • 监管机构日益重视单核细胞活化试验在药物品管中用于评估致热性的作用

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第8章 单核球活化试验市场依产品类型划分

  • 装置
    • ELISA 阅读器
    • 流式细胞仪
    • 微阵列扫描仪
  • 试剂盒和试剂
    • 细胞培养基
    • 细胞激素检测试剂
    • 单核球活化试剂
  • 服务
    • 合约测试服务
    • 客製化检测开发
    • 验证服务

第九章 单核细胞活化试验市场（依应用领域划分）

  • 生技药品的安全性
    • 细胞疗法
    • 单株抗体
    • 重组蛋白
  • 细胞疗法
    • 树突状细胞
    • 干细胞
    • T细胞
  • 疫苗安全性
    • 失活
    • 活病毒疫苗
    • 次单元

第十章 单核细胞活化检测市场（依技术划分）

  • ELISA
    • 竞争性ELISA
    • 夹心ELISA
  • 流式细胞技术
    • 细胞内细胞激素染色组
    • 表面标誌物面板
  • 微阵列
    • DNA微阵列
    • 蛋白质微阵列
  • 次世代定序
    • RNA定序
    • 标靶定序

第十一章 单核球活化检测市场（依最终用户划分）

  • CRO
    • 全方位CRO服务
    • 利基CRO
  • 医院和诊断机构
    • 社区医院
    • 诊断检查室
    • 大学医院
  • 製药和生物技术
    • 大型製药企业
    • 中型生技公司
    • 小规模生技公司
  • 研究所
    • 学术机构
    • 政府
    • 非营利组织

第十二章 单核细胞活化检测市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 单核球活化试验市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 单核球活化检测市场（依国家划分）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Lonza Group AG
    • Merck KGaA
    • Sartorius AG
    • Charles River Laboratories International, Inc.
    • bioMerieux SA
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company
    • GenScript Biotech Corporation
    • Inotiv, Inc.
    • WuXi AppTec Co., Ltd.
Product Code: MRR-69324464D064

The Monocyte Activation Tests Market is projected to grow by USD 1,090.85 million at a CAGR of 8.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 585.09 million
Estimated Year [2025] USD 629.21 million
Forecast Year [2032] USD 1,090.85 million
CAGR (%) 8.09%

An essential introduction to how monocyte activation testing bridges immunotoxicology, biotherapeutic safety, and clinical laboratory practice in a rapidly evolving life sciences ecosystem

Monocyte activation tests have emerged as critical assays bridging immunotoxicology, biotherapeutic safety, and clinical diagnostics. These tests evaluate the innate immune response by measuring functional activation of monocytes following exposure to pharmaceutical substances, vaccine candidates, or biological contaminants. As therapies become increasingly complex and biologics dominate pipelines, regulatory agencies and clinical laboratories seek robust, reproducible methods to detect immunostimulatory impurities and to ensure safety across manufacturing and clinical stages.

In recent years, technological advances have improved sensitivity and throughput, while assay standardization efforts have increased the reproducibility of results across laboratories. This evolution has coincided with broader shifts in therapeutic modalities, including cell and gene therapies, which introduce unique safety considerations that monocyte activation tests can help address. Consequently, stakeholders from diagnostics vendors to contract research laboratories are reevaluating their test portfolios and validation approaches to align with emergent clinical and regulatory expectations.

Going forward, an integrated perspective that combines instrument innovation, reagent specificity, and service-oriented testing workflows will be essential for organizations seeking to maintain compliance and to deliver high-confidence safety data. This introduction frames the subsequent sections, which explore transformative industry shifts, tariff-related implications for the United States in 2025, segmentation-driven insights, regional dynamics, competitive positioning, tactical recommendations, methodological rigor, and a succinct conclusion that synthesizes the executive implications for decision-makers.

How recent technological advances, shifting regulatory expectations, and integrated solution models are fundamentally reshaping monocyte activation testing and adoption dynamics

The landscape for monocyte activation testing is undergoing transformative shifts driven by technological innovation, evolving regulatory expectations, and a growing emphasis on translational safety assessment. High-sensitivity detection platforms and hybrid assay formats have expanded the analytical window of these tests, enabling earlier and more precise identification of immunostimulatory signals within complex biological matrices. This technological maturation is reshaping workflows, where laboratories increasingly combine instrument-based readouts with advanced bioinformatics to improve signal interpretation and reduce false positives.

Concurrent with instrument innovation, there is a marked shift toward integrated reagent ecosystems and standardized assay kits that lower the barrier to adoption for clinical and commercial laboratories. As a result, vendors are moving from standalone product sales to bundled solutions that include assay validation data, quality controls, and post-sale support, thereby accelerating deployment across diverse end users. These bundled offerings are supported by an expanding services market, where contract testing providers offer bespoke assay development and validation services to help biopharma clients meet complex regulatory requirements.

Regulatory expectations are also evolving, with agencies signaling a preference for assays that demonstrate clear clinical relevance and validated performance characteristics. This regulatory momentum is prompting closer collaboration between manufacturers and regulators to harmonize performance criteria and to develop guidance documents that balance safety assurance with innovation. Taken together, these shifts are creating a more modular, interoperable ecosystem in which cross-disciplinary collaboration and data transparency are increasingly rewarded, and where early investment in robust assay design yields competitive differentiation.

An examination of how cumulative tariff pressures up to 2025 have reshaped supply chains, sourcing strategies, and operational models across monocyte activation testing stakeholders

The cumulative impact of United States tariff policies enacted through 2025 has introduced new operational considerations for manufacturers and laboratories involved in monocyte activation testing. Tariff-driven cost pressures have affected supply chains for specialized instruments, reagents, and consumables that are frequently sourced across international partners. In response, some vendors have diversified supplier networks and localized certain production steps to reduce exposure to import duties and to improve supply chain resilience. These strategic adjustments have implications for lead times, unit cost structures, and vendor selection criteria.

Moreover, tariff influences extend beyond direct cost inflation. They have prompted reassessment of cross-border service agreements and collaborative R&D arrangements, as providers weigh the administrative burden and potential delays associated with tariff classifications and customs clearance. Consequently, contract testing providers and biopharma companies have prioritized contractual flexibility and inventory management strategies that buffer against tariff volatility. This has led to an increased preference for multi-sourcing strategies and for long-term supplier agreements that can lock in pricing or provide greater predictability.

Importantly, tariff effects have also accelerated conversations about regional manufacturing and nearshoring. For some organizations, shifting production closer to key end markets reduces tariff exposure and shortens supply chains, albeit at the expense of initial capital outlay. From a regulatory and quality perspective, nearshoring can streamline regulatory filings and inspections because localized manufacturing often aligns more directly with regional compliance frameworks. Ultimately, the cumulative effect of tariff dynamics has been to push stakeholders toward supply chain diversification, contractual risk-sharing, and operational models that prioritize continuity and cost predictability over single-source efficiencies.

A nuanced segmentation perspective that maps products, applications, technologies, and end users to strategic opportunity and prioritization in monocyte activation testing

Understanding key segmentation dynamics is essential to navigate the monocyte activation testing market and to design product and go-to-market strategies that align with end-user needs. Based on product type, the market comprises instruments, kits and reagents, and services, where instruments cover ELISA readers, flow cytometers, and microarray scanners, and kits and reagents encompass cell culture media, cytokine detection reagents, and monocyte activation reagents, while services include contract testing services, custom assay development, and validation services; this product-centric view clarifies where innovation is concentrated and where partnerships can accelerate time-to-market.

From an application perspective, the market is oriented around biotherapeutic safety, cell therapy, and vaccine safety. Biotherapeutic safety includes testing for cell therapies, monoclonal antibodies, and recombinant proteins, reflecting the need for tailored assays that address modality-specific impurity profiles. Cell therapy applications further subdivide into dendritic cells, stem cells, and T cells, each presenting unique activation patterns and matrix complexities that require specialized assay formats. Vaccine safety covers inactivated, live attenuated, and subunit vaccines, with assay sensitivity and dynamic range tuned to the diverse immunogenic characteristics of these platforms.

Technologically, ELISA, flow cytometry, microarray, and next-generation sequencing platforms underpin assay capabilities. ELISA methodologies differentiate into competitive and sandwich formats, while flow cytometry applications span intracellular cytokine staining panels and surface marker panels. Microarray approaches bifurcate into DNA and protein microarrays, and sequencing modalities include RNA-Seq and targeted sequencing; these technical distinctions inform performance trade-offs between throughput, multiplexing capacity, and sensitivity. Lastly, the end-user landscape comprises contract research organizations, hospitals and diagnostics providers, pharmaceuticals and biotech companies, and research institutes. Contract research organizations can be full-service or niche, hospitals and diagnostics range from community to university settings, pharmaceuticals and biotech vary by scale from large to small, and research institutes include academic, government, and non-profit entities; understanding these end-user categories helps vendors prioritize sales channels, support models, and service-level agreements that reflect customer operational realities.

Regional dynamics and adoption patterns across the Americas, Europe Middle East and Africa, and Asia-Pacific that determine deployment, regulation, and commercialization pathways

Regional dynamics significantly influence adoption rates, regulatory pathways, and commercialization strategies for monocyte activation testing. In the Americas, strong biopharma ecosystems and established regulatory frameworks create a favorable environment for advanced assay adoption, with dense networks of contract laboratories and early adopters in clinical research driving demand. This region benefits from proximity to large clinical trial sites and headquarters of major therapeutic developers, which facilitates pilot programs and collaborative validation studies.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization and local standards vary, leading to differentiated adoption curves. In several European markets, robust public research funding and collaborative consortia have supported standardized assay protocols and cross-laboratory comparisons, while markets in the Middle East and Africa often prioritize capacity building and localized training initiatives to expand testing infrastructure. These regional nuances require vendors to tailor regulatory support, educational outreach, and pricing models to reflect local procurement practices and institutional capabilities.

Asia-Pacific is characterized by rapid expansion in biomanufacturing capacity and accelerating investment in advanced diagnostics. This region includes both highly developed markets with sophisticated regulatory regimes and emerging markets where demand is driven by local production needs and public health priorities. Manufacturers seeking to scale across Asia-Pacific must account for variable reimbursement landscapes, differing clinical validation expectations, and opportunities for strategic partnerships with regional distributors and research institutions. Across all regions, interoperability, data standardization, and localized technical support remain critical enablers of sustained adoption.

Key competitive dynamics and company strategies that differentiate instrument makers, reagent specialists, and service providers in the monocyte activation testing ecosystem

Competitive positioning in monocyte activation testing reflects a mixture of established instrument manufacturers, specialty reagent suppliers, and service-focused contract providers that each pursue differentiated value propositions. Instrument vendors compete on sensitivity, throughput, and integration capabilities, often coupling hardware with proprietary software and reagent bundles to create stickiness. Reagent suppliers emphasize assay specificity, stability, and regulatory-grade quality controls to win preference among validation-focused customers. At the same time, service providers distinguish themselves through flexible study designs, rapid turnaround, and deep regulatory expertise that help biopharma clients accelerate timelines and de-risk submissions.

Strategic activity across companies includes collaborative partnerships, co-development agreements, and expansions of service portfolios to capture adjacent revenue streams. Firms that invest in robust validation datasets and transparent performance metrics gain credibility with regulatory stakeholders and clinical customers. Additionally, companies that offer modular service packages-ranging from assay development to full validation and ongoing lot-release testing-tend to form longer-term relationships with biopharma and vaccine manufacturers. Observing these competitive dynamics, executives should evaluate partner capabilities not only by product specifications but also by the strength of technical support, training programs, and demonstrated success in regulatory contexts.

Actionable strategic recommendations to strengthen product validation, integrated offerings, supply chain resilience, customer enablement, and data interoperability for market leadership

Industry leaders should take immediate, actionable steps to protect market position and to accelerate value creation in monocyte activation testing. First, prioritize investments in assay standardization, performance validation, and the creation of comprehensive technical documentation that facilitates regulatory review and cross-laboratory reproducibility. These efforts will reduce customer friction and increase confidence in your offerings. Second, cultivate multi-channel partnerships that blend instrument sales with reagent supply and service delivery, thereby creating integrated solution bundles that address end-to-end customer needs and increase revenue predictability.

Third, strengthen supply chain resilience by diversifying suppliers and evaluating nearshoring opportunities for critical components and reagents; this approach mitigates tariff exposure and reduces lead-time uncertainty. Fourth, expand training and post-sale support capabilities to improve customer outcomes and to lower the barrier to adoption among non-specialist laboratories. Finally, invest in data interoperability and analytical tools that enhance result interpretation and enable downstream integration with clinical and manufacturing quality systems. By operationalizing these recommendations, leaders will enhance market credibility, accelerate customer adoption, and improve long-term commercial resilience.

A concise explanation of the rigorous mixed methods research approach combining stakeholder interviews, regulatory review, and technical performance synthesis used to develop these insights

The research behind this executive summary employed a mixed-methods approach to synthesize technical, regulatory, and commercial insights. Primary research included structured interviews with laboratory directors, validation scientists, and procurement managers, as well as consultative engagements with regulatory specialists to capture nuanced perspectives on assay acceptance criteria. Secondary research encompassed a review of peer-reviewed literature, regulatory guidance documents, and product technical specifications to validate performance claims and to contextualize technology trade-offs.

Qualitative analysis prioritized triangulation of sources to ensure that assertions about adoption drivers and barriers were corroborated across stakeholder groups. The methodology also integrated comparative assessments of instrument performance, reagent stability, and service delivery models to identify patterns that indicate durable competitive advantages. Throughout the research, attention was paid to reproducibility, transparency of assumptions, and the use of standardized descriptors for assay formats and end-user categories. This methodological rigor supports the reliability of the insights presented and ensures that recommendations are actionable and grounded in validated evidence.

A concise conclusion synthesizing implications for strategy, validation priorities, and operational resilience that determine long-term advantage in monocyte activation testing

In conclusion, monocyte activation testing sits at the intersection of scientific innovation, regulatory scrutiny, and operational complexity. The maturation of assay technologies and the growing need for reliable immunotoxicity assessment have elevated the strategic importance of these tests for biotherapeutic developers and clinical laboratories. At the same time, external pressures such as tariff dynamics and regional regulatory variability necessitate adaptive commercial strategies and resilient supply chains.

Organizations that invest in assay standardization, integrated solution models, and robust validation evidence will be best positioned to capture opportunity and to support safe product development. Collaborative partnerships that combine instrument capability, reagent specificity, and service excellence will continue to differentiate market leaders. Ultimately, stakeholders who translate these insights into focused operational changes-improving reproducibility, expanding technical support, and diversifying sourcing-will create the most durable competitive advantage in the evolving monocyte activation testing landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of automated microfluidic platforms for real-time monocyte activation analysis in regulatory testing
  • 5.2. Integration of artificial intelligence algorithms to predict monocyte activation profiles in personalized medicine pipelines
  • 5.3. Development of multiplexed flow cytometry assays for simultaneous detection of monocyte activation biomarkers
  • 5.4. Emergence of standardized monocyte activation test kits for endotoxin detection in cell therapy manufacturing
  • 5.5. Expansion of contract research organization services for customized monocyte activation testing in vaccine development
  • 5.6. Increasing regulatory emphasis on monocyte activation testing for pyrogenicity assessment in pharmaceutical quality control

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Monocyte Activation Tests Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. ELISA Readers
    • 8.1.2. Flow Cytometers
    • 8.1.3. Microarray Scanners
  • 8.2. Kits & Reagents
    • 8.2.1. Cell Culture Media
    • 8.2.2. Cytokine Detection Reagents
    • 8.2.3. Monocyte Activation Reagents
  • 8.3. Services
    • 8.3.1. Contract Testing Services
    • 8.3.2. Custom Assay Development
    • 8.3.3. Validation Services

9. Monocyte Activation Tests Market, by Application

  • 9.1. Biotherapeutic Safety
    • 9.1.1. Cell Therapies
    • 9.1.2. Monoclonal Antibodies
    • 9.1.3. Recombinant Proteins
  • 9.2. Cell Therapy
    • 9.2.1. Dendritic Cells
    • 9.2.2. Stem Cells
    • 9.2.3. T Cells
  • 9.3. Vaccine Safety
    • 9.3.1. Inactivated
    • 9.3.2. Live Attenuated
    • 9.3.3. Subunit

10. Monocyte Activation Tests Market, by Technology

  • 10.1. ELISA
    • 10.1.1. Competitive ELISA
    • 10.1.2. Sandwich ELISA
  • 10.2. Flow Cytometry
    • 10.2.1. Intracellular Cytokine Staining Panels
    • 10.2.2. Surface Marker Panels
  • 10.3. Microarray
    • 10.3.1. DNA Microarray
    • 10.3.2. Protein Microarray
  • 10.4. Next-Gen Sequencing
    • 10.4.1. RNA-Seq
    • 10.4.2. Targeted Sequencing

11. Monocyte Activation Tests Market, by End User

  • 11.1. CROs
    • 11.1.1. Full-Service CROs
    • 11.1.2. Niche CROs
  • 11.2. Hospitals & Diagnostics
    • 11.2.1. Community Hospitals
    • 11.2.2. Diagnostic Labs
    • 11.2.3. University Hospitals
  • 11.3. Pharmaceuticals & Biotech
    • 11.3.1. Large Pharma
    • 11.3.2. Mid-Size Biotech
    • 11.3.3. Small Biotech
  • 11.4. Research Institutes
    • 11.4.1. Academic
    • 11.4.2. Government
    • 11.4.3. Non-Profit

12. Monocyte Activation Tests Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Monocyte Activation Tests Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Monocyte Activation Tests Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Lonza Group AG
    • 15.3.2. Merck KGaA
    • 15.3.3. Sartorius AG
    • 15.3.4. Charles River Laboratories International, Inc.
    • 15.3.5. bioMerieux SA
    • 15.3.6. Thermo Fisher Scientific Inc.
    • 15.3.7. Becton, Dickinson and Company
    • 15.3.8. GenScript Biotech Corporation
    • 15.3.9. Inotiv, Inc.
    • 15.3.10. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MONOCYTE ACTIVATION TESTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MONOCYTE ACTIVATION TESTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MONOCYTE ACTIVATION TESTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA READERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA READERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA READERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA READERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA READERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA READERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY KITS & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY KITS & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL CULTURE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL CULTURE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL CULTURE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL CULTURE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL CULTURE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CYTOKINE DETECTION REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CYTOKINE DETECTION REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CYTOKINE DETECTION REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CYTOKINE DETECTION REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CYTOKINE DETECTION REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CYTOKINE DETECTION REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCYTE ACTIVATION REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCYTE ACTIVATION REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCYTE ACTIVATION REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCYTE ACTIVATION REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCYTE ACTIVATION REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCYTE ACTIVATION REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CONTRACT TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CONTRACT TESTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CONTRACT TESTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CONTRACT TESTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CONTRACT TESTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CONTRACT TESTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CUSTOM ASSAY DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CUSTOM ASSAY DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CUSTOM ASSAY DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CUSTOM ASSAY DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CUSTOM ASSAY DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CUSTOM ASSAY DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VALIDATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VALIDATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VALIDATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VALIDATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VALIDATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VALIDATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY BIOTHERAPEUTIC SAFETY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY BIOTHERAPEUTIC SAFETY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY BIOTHERAPEUTIC SAFETY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY BIOTHERAPEUTIC SAFETY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY BIOTHERAPEUTIC SAFETY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY BIOTHERAPEUTIC SAFETY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY BIOTHERAPEUTIC SAFETY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY BIOTHERAPEUTIC SAFETY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY T CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY T CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY T CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY T CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY T CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY T CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VACCINE SAFETY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VACCINE SAFETY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VACCINE SAFETY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VACCINE SAFETY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VACCINE SAFETY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VACCINE SAFETY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VACCINE SAFETY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY VACCINE SAFETY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INTRACELLULAR CYTOKINE STAINING PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INTRACELLULAR CYTOKINE STAINING PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INTRACELLULAR CYTOKINE STAINING PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INTRACELLULAR CYTOKINE STAINING PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INTRACELLULAR CYTOKINE STAINING PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY INTRACELLULAR CYTOKINE STAINING PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SURFACE MARKER PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SURFACE MARKER PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SURFACE MARKER PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SURFACE MARKER PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SURFACE MARKER PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY SURFACE MARKER PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DNA MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DNA MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DNA MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DNA MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DNA MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DNA MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PROTEIN MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PROTEIN MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PROTEIN MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PROTEIN MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PROTEIN MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PROTEIN MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RNA-SEQ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RNA-SEQ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RNA-SEQ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RNA-SEQ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RNA-SEQ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY RNA-SEQ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CROS, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CROS, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CROS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CROS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CROS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CROS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CROS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY CROS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FULL-SERVICE CROS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FULL-SERVICE CROS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FULL-SERVICE CROS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FULL-SERVICE CROS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FULL-SERVICE CROS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY FULL-SERVICE CROS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NICHE CROS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NICHE CROS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NICHE CROS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NICHE CROS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NICHE CROS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY NICHE CROS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY HOSPITALS & DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY HOSPITALS & DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY HOSPITALS & DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY HOSPITALS & DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY HOSPITALS & DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY HOSPITALS & DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY HOSPITALS & DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY HOSPITALS & DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DIAGNOSTIC LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DIAGNOSTIC LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DIAGNOSTIC LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY DIAGNOSTIC LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY UNIVERSITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY UNIVERSITY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY UNIVERSITY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY UNIVERSITY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY UNIVERSITY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY UNIVERSITY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PHARMACEUTICALS & BIOTECH, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL MONOCYTE ACTIVATION TESTS MARKET SIZE, BY PHARMACEUTICALS & BIOTECH, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL MONOCYTE ACTIVAT